Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2022, our revenue amounted to SEK 18.8 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.